A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Conditions

• Cystic Fibrosis

Interventions

• DRUG: VX-661/Ivacaftor
• DRUG: Ivacaftor
• DRUG: Placebo matched to VX-661/ ivacaftor
• DRUG: Placebo matched to Ivacaftor

Sponsor

Vertex Pharmaceuticals Incorporated